GlassScriptPhysician profile
Paul Thomas Lui
NPI 1114923687
$4,138.63
in general payments reported to CMS, 2019-2025
34 companies · $831 in 2025
The $831 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $557 · 2020: $275 · 2021: $436 · 2022: $606 · 2023: $702 · 2024: $733 · 2025: $831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,243 · Education: $21.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,243.15 |
| Education | $21.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $652.07 | 2019-2025 | Lokelma, Farxiga |
| Amgen INC. | $330.06 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Otsuka America Pharmaceutical, INC. | $297.07 | 2019-2025 | Jynarque |
| Fresenius USA Marketing, INC. | $266.30 | 2019-2024 | Velphoro |
| Glaxosmithkline, LLC. | $219.96 | 2021-2024 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $185.51 | 2021-2025 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $157.79 | 2021-2025 | |
| Vifor Pharma, INC. | $151.32 | 2019-2023 | Veltassa |
| Vantive US Healthcare LLC | $149.33 | 2025 | Renal - Pd |
| Abbott Laboratories | $143.94 | 2023 | Cardiomems |
| Alnylam Pharmaceuticals INC. | $128.41 | 2022-2025 | Givlaari |
| Sanofi-Aventis U.S. LLC | $125.00 | 2025 | |
| Novo Nordisk INC | $123.72 | 2023-2025 | Ozempic, Wegovy, Rivfloza |
| Nxstage Medical, INC. | $115.81 | 2020-2024 | Nxstage System One |
| Travere Therapeutics, INC. | $115.67 | 2023-2025 | Filspari |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $113.81 | 2021-2025 | |
| Baxter Healthcare | $111.47 | 2024 | |
| Horizon Therapeutics Plc | $101.31 | 2019-2023 | Krystexxa |
| Ardelyx, INC. | $80.47 | 2024-2025 | Ibsrela |
| Veloxis Pharmaceuticals, INC. | $78.94 | 2024 | Envarsus |
| Alexion Pharmaceuticals, INC. | $77.99 | 2019-2023 | Ultomiris |
| Lundbeck LLC | $73.68 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $52.98 | 2025 | Jardiance |
| Daiichi Sankyo INC. | $44.15 | 2021-2025 | Injectafer |
| Calliditas Therapeutics US INC. | $41.36 | 2022-2023 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $39.79 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $27.99 | 2019 | |
| Aurinia Pharma U.S., INC. | $25.24 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $23.64 | 2024 | |
| Recordati_rare_diseases_inc. | $22.84 | 2025 | Cystadrops |
| Tanabe Pharma America, INC. | $20.99 | 2025 | Radicava |
| Apellis Pharmaceuticals, INC. | $14.96 | 2025 | |
| Lilly USA, LLC | $13.46 | 2025 | Jardiance |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Lui listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.